Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.

Metastases burden, LDH levels, and RLC are independent baseline characteristics associated with outcome in patients with melanoma receiving anti-PD-1. Further investigations are needed to clarify if evaluation of these parameters can translate into clinical strategy and apply to patient selection.